UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number: 001-39458
Medicenna Therapeutics Corp.
(Translation of registrant’s name into English)
2 Bloor St. W. 7th Floor
Toronto, Ontario M4W 3E2
Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| x Form 20-F | ¨ Form 40-F |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Medicenna Therapeutics Corp. | |||
| (Registrant) | |||
| Date: April 30, 2024 | By: | /s/ Fahar Merchant | |
| Name: | Fahar Merchant, PhD | ||
| Title: | Chief Executive Officer | ||
Form 6-K Exhibit Index
| Exhibit Number |
Document Description | |
| 99.1 | Press Release of the Registrant dated April 30, 2024 | |
| 99.2 | Material Change Report of the Registrant dated April 30, 2024 | |
| 99.3 | Pre-Funded Warrant Certificate |